Frontiers | Remarkable Response of EGFR- and HER2-Amplified Metastatic Colon Cancer to Pyrotinib After Failed Multiline Treatments: A Case Report and Literature Review
Assessment of a HER2 scoring system for colorectal cancer: results from a validation study | Modern Pathology
Mechanisms of resistance to anti-epidermal growth factor receptor inhibitors in metastatic colorectal cancer
Dual HER2 Blockade in Patients With HER2-Amplified Metastatic
HER2 Biomarker in Colon Cancer | Know Your Biomarker
Comprehensive assessment of HER2 alteration in a colorectal cancer coh | CMAR
Q&A column - CAP TODAY
The predictive role of ERBB2 point mutations in metastatic colorectal cancer: A systematic review - ScienceDirect
HER2 Biomarker | Colorectal Cancer Alliance
IJMS | Free Full-Text | Beyond RAS and BRAF: HER2, a New Actionable Oncotarget in Advanced Colorectal Cancer
HER2 in Colorectal Cancer: The Long and Winding Road From Negative Predictive Factor to Positive Actionable Target | American Society of Clinical Oncology Educational Book
HER2 Biomarker | Colorectal Cancer Alliance
Pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer (MyPathway): an updated report from a multicentre, open-label, phase 2a, multiple basket study - The Lancet Oncology
Clinical significance of HER2 and EGFR expression in colorectal cancer patients with ovarian metastasis | BMC Clinical Pathology | Full Text
Precision Cancer Medicines for Colon Cancer - CancerConnect
Frontiers | Human Epidermal Growth Factor Receptor 2 Overexpression and Amplification in Patients With Colorectal Cancer: A Large-Scale Retrospective Study in Chinese Population
HER2/neu testing in primary colorectal carcinoma | British Journal of Cancer
IJMS | Free Full-Text | Beyond RAS and BRAF: HER2, a New Actionable Oncotarget in Advanced Colorectal Cancer
Tucatinib Approved for HER2-Positive Colorectal Cancer - NCI
![HER2 and BRAF mutation in colorectal cancer patients: a retrospective study in Eastern China [PeerJ]](https://dfzljdn9uc3pi.cloudfront.net/2020/8602/1/fig-5-2x.jpg "HER2 and BRAF mutation in colorectal cancer patients: a retrospective study in Eastern China [PeerJ]")
HER2 and BRAF mutation in colorectal cancer patients: a retrospective study in Eastern China [PeerJ]
Dual HER2 Blockade in Patients With HER2-Amplified Metastatic
Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial - The Lancet Oncology
![PDF] Dual HER2 inhibition strategies in the management of treatment-refractory metastatic colorectal cancer: History and status | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/94e7ce3cbf29365fa3c4053b007a40513f46b3af/3-Figure1-1.png "PDF] Dual HER2 inhibition strategies in the management of treatment-refractory metastatic colorectal cancer: History and status | Semantic Scholar")